Fig. 5
From: Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression
Combination of lamivudine and sorafenib can reduce HBV+ liver tumor growth in mouse model. Nude BALB/c mice were first injected with HepG2 or HepG2.215 cells to form tumors. Then mice were either mock treated with solvent, or treated with sorafenib, or sorafenib and lamivudine. Tumor volume and mice weight were measured every 3 days. Tumor weight was measured at the day of mice sacrifice. Data shown are mean ± SD of three independent experiments. ns, not statistically significant; *, p < 0.05; **, p < 0.01